RecruitingNot ApplicableNCT04252781

Incident Chronic Obstructive pulmoNary dIsease Cohort Study (ICONIC)


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

300 participants

Start Date

Aug 20, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

Chronic Obstructive Pulmonary Disease (COPD), , secondary to smoking, is a major public health issue with very high direct and indirect costs. The impact on the health system of undiagnosed patients, up to 70% of patients, is increasingly documented. However, systematic spirometry screening remains controversial among smokers in the absence of data to link the detection of new patients with improved management and clinical events and health goals. More generally, there is little data on the evolution of patients in real life once they have entered the care system. The premise is that with systematic screening in general medicine, it is possible to identify the evolution of newly diagnosed COPD patients, to distinguish the different possible evolutions according to the initial phenotype and the management.


Eligibility

Min Age: 35 Years

Inclusion Criteria6

  • Age\> 35 years
  • Smoking \> 20 PA
  • Active smoking (cessation \< 1 month)
  • Signature of consent to participate in Phase I of the study
  • FEV1 / FVC \<70% of the theoretical value and / or \<LLN (Lower limit of normal)
  • Signature of consent to participate in Phase II of the study

Exclusion Criteria5

  • Known COPD
  • Cancer being treated
  • No affiliation to the social security or other social protection scheme
  • Pregnant or lactating woman
  • Patient deprived of liberty or under legal protection (under tutorship or curatorship

Interventions

OTHERExhaustive exploration

* clinical investigations * imagery * blood assessment * functional respiratory investigations * muscle function / skeletal muscle index


Locations(1)

Hopital Henri MONDOR

Créteil, Île-de-France Region, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04252781


Related Trials